Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X, Sun L, Song N, He W, Xie B, Hu J, Zhang J, Yang J, Dai J, Bian D, Xia H, Sun F, Xiong A, Luo J, Zhang L, Yu H, Liu M, Liu H, Wang H, Zhang H, Chen C, Wu C, Duan L, Zhu Y, Zhang P, Jiang G.
Zhu X, et al. Among authors: zhang l, zhang p, zhang j, zhang h.
BMC Med. 2022 Dec 30;20(1):493. doi: 10.1186/s12916-022-02696-4.
BMC Med. 2022.
PMID: 36581917
Free PMC article.
Clinical Trial.